---
layout: default
title: Alprostadil
parent: 僅模型預測 (L5)
nav_order: 24
evidence_level: L5
indication_count: 10
---

# Alprostadil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alprostadil: Preliminary Evaluation — Awaiting TxGNN Prediction Data

## One-Sentence Summary

Alprostadil (prostaglandin E1) is a vasodilatory prostaglandin analogue known for its use in patent ductus arteriosus maintenance and erectile dysfunction. The TxGNN model has **not yet generated predicted indications** for this drug, and no original indications are recorded in the current evidence pack. This report serves as a baseline assessment pending completion of the prediction pipeline.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in current evidence pack |
| Predicted New Indication | — (No TxGNN prediction available) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No prediction or supporting studies) |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not produced any predicted new indications for Alprostadil. Without a specific predicted indication, a mechanistic plausibility analysis cannot be performed at this time.

Alprostadil is a synthetic form of prostaglandin E1 (PGE1). Detailed mechanism of action data was not available in the evidence pack; however, it is well established that Alprostadil acts as a vasodilator by relaxing vascular smooth muscle via activation of adenylate cyclase and elevation of intracellular cAMP. It also inhibits platelet aggregation. These properties underlie its clinical use in maintaining patency of the ductus arteriosus in neonates with congenital heart defects, and in treating erectile dysfunction through local vasodilation.

Once the TxGNN prediction pipeline is executed for this drug, a full mechanistic rationale linking the original and predicted indications can be developed.

## Clinical Trial Evidence

Currently no TxGNN-predicted indications are available; therefore, targeted clinical trial evidence cannot be compiled at this stage.

## Literature Evidence

Currently no TxGNN-predicted indications are available; therefore, targeted literature evidence cannot be compiled at this stage.

## Taiwan Market Information

Alprostadil currently holds **no active marketing authorizations** from TFDA (Taiwan FDA). No licensed products are registered in Taiwan at this time.

## Safety Considerations

> Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack.

## Data Gaps Identified

The following critical data gaps have been flagged and must be resolved before proceeding:

| Gap ID | Item | Severity | Impact | Remediation |
|--------|------|----------|--------|-------------|
| DG001 | TFDA Package Insert Warnings/Contraindications | **Blocking** | Cannot enter Stage 1 safety assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Mechanism of Action (MOA) | High | Affects mechanistic relevance analysis | Query DrugBank API |

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN-predicted indications have been generated for Alprostadil, and the drug currently has no marketing authorization in Taiwan. Multiple blocking data gaps exist that prevent safety evaluation. The evaluation cannot advance until prediction data is available.

**To proceed, the following is needed:**
- Complete the TxGNN prediction pipeline to generate candidate new indications for Alprostadil
- Resolve **DG001** (Blocking): Obtain and parse TFDA package insert for safety warnings and contraindications
- Resolve **DG002** (High): Retrieve detailed mechanism of action data from DrugBank
- Investigate Taiwan market availability or identify alternative regulatory pathways if repurposing candidates are identified
- Once predictions are available, conduct targeted PubMed and ClinicalTrials.gov evidence searches for the top-ranked indications
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

